Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.39 |
| ▸ | SLC2A9 | Q9NRM0 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 7/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | GALK1 | P51570 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458928 | 1.00 | SLC22A12 (0.39) | SLC22A12SLC2A9AKR1C3APEX1POLB | |
| SCHEMBL16395615 | 0.83 | SLC22A12 (0.34) | SLC22A12SLC2A9 | |
| SCHEMBL9960738 | 0.77 | POLB (0.35) | POLBAPAF1TDP2NSD2CYP1A2 | |
| SCHEMBL9960569 | 0.76 | APEX1 (0.50) | AKR1C3APEX1POLBCYP2C9 | |
| SCHEMBL2530115 | 0.74 | AKR1B1 (0.41) | POLBCYP1A2MAPT | |
| SCHEMBL5138671 | 0.74 | KDM4E (0.39) | SLC22A12SLC2A9AKR1C3APEX1POLB | |
| SCHEMBL28015994 | 0.72 | ACHE (0.34) | POLBCYP1A2CYP2C19 | |
| SCHEMBL5484988 | 0.72 | POLB (0.42) | AKR1C3APEX1POLBMAPTKMT2A | |
| SCHEMBL2426303 | 0.72 | KEAP1 (0.44) | APEX1CYP1A2MAPT | |
| SCHEMBL17060190 | 0.71 | PAM (0.40) | KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332115-A1 | CONTROLLED EXPRESSION OF THERAPEUTICALLY RELEVANT BIOMOLECULES FOR LUMEN-LOCALIZED PAYLOADS IN BIOMIMETIC NANOVESICLES AND EXOSOMES | MALCOLM THOMAS (US) | 2025-10-30 | — | — | US | claimed |
| CN-119859656-A | Method, composition, kit and application for transfecting cells with molecules | 诺丁汉大学 | 2025-04-22 | — | — | CN | claimed |
| US-20240182864-A1 | NOVEL CHEMICAL COMBINATIONS AND METHODS OF USE THEREOF, TOWARDS DIFFERENTIATION OF HUMAN PROGENITOR CELLS INTO FUNCTIONAL BETA CELLS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2024-06-06 | — | — | US | claimed |
| US-20230193205-A1 | GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS | FIGENE, LLC | 2023-06-22 | — | — | US | claimed |
| WO-2023033128-A1 | METHOD FOR PRODUCING PROTEIN | 国立大学法人京都大学 | 2023-03-09 | — | — | WO | claimed |
| WO-2022173241-A1 | COMPOSITON FOR CONTROLLING SUGAR, CONTAINING ATYPICAL PKC ACTIVATOR | 연세대학교 산학협력단 | 2022-08-18 | — | — | WO | claimed |
| US-20220213178-A1 | Enhanced Transfection | THE UNIVERSITY OF NOTTINGHAM (GB) | 2022-07-07 | — | — | US | claimed |
| US-20220062345-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PROTEIN KINASE C ACTIVATOR-TREATED STEM CELLS OR CULTURE THEREOF FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES | CORESTEM CO.,LTD. (JP) | 2022-03-03 | — | — | US | claimed |
| CN-114072182-A | Enhanced transfection | 诺丁汉大学 | 2022-02-18 | — | — | CN | claimed |
| EP-3941529-A1 | ENHANCED TRANSFECTION | The University of Nottingham (GB) | 2022-01-26 | — | — | EP | claimed |
| WO-2015055987-A1 | NEURONAL STEM CELL DIFFERENTIATION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2015-04-23 | — | — | WO | claimed |
| EP-1988877-B1 | THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE | LEO LAB LTD (IE) | 2014-02-12 | — | — | EP | claimed |
| US-20120039805-A1 | Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample | PANGEA BIOSCIENCES, INC. | 2012-02-16 | — | — | US | claimed |
| EP-2399571-A1 | Therapeutic compositions comprising ingenol-3-angelate | Peplin Research Pty Ltd. (AU) | 2011-12-28 | — | — | EP | claimed |
| WO-2011050947-A2 | TAPE, IN PARTICULAR, ADHESIVE TAPE, FOR THE TREATMENT OF SKIN DISORDERS COMPRISING AT LEAST ONE HYPERKERATOSIS INHIBITOR AND/OR AT LEAST ONE KERATINOLYTIC AGENT | JOHNSON & JOHNSON GMBH (DE) | 2011-05-05 | — | — | WO | claimed |
| EP-2316438-A1 | Tape , in particular adhesive tape, for the treatment of skin disorders comprising at least one hyperkeratosis inhibitor and/or at least one keratinolytic agent | Johnson & Johnson GmbH (DE) | 2011-05-04 | — | — | EP | claimed |
| WO-2010096627-A1 | THERAPEUTICS AND METHODS FOR TREATING NEOPLASTIC DISEASES COMPRISING DETERMINING THE LEVEL OF CAVEOLIN-1 AND/OR CAVEOLIN-2 IN A STROMAL CELL SAMPLE | LISANTI MICHAEL P (US) | 2010-08-26 | — | — | WO | claimed |
| US-20090292017-A1 | THERAPEUTIC COMPOSITIONS | PEPLIN RESEARCH PTY LIMITED | 2009-11-26 | — | — | US | claimed |
| EP-1988877-A2 | THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE | Peplin Research Pty Ltd. (AU) | 2008-11-12 | — | — | EP | claimed |
| WO-2007068963-A2 | THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE | PEPLIN RESEARCH PTY LTD (AU) | 2007-06-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292017-A1 | THERAPEUTIC COMPOSITIONS | TP53, ERGIC1, MCL1 | SLC22A12 1949/4885SLC2A9 2570/4885AKR1C3 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.